Fate Therapeutics to Present at Upcoming May Investor Conferences

Rhea-AI Summary

Fate Therapeutics, a clinical-stage biopharmaceutical company focused on cellular immunotherapies, announced its participation in two upcoming investor conferences. The BofA Securities 2022 Healthcare Conference will be held on May 12, 2022, at 12:20 PM ET in Las Vegas, Nevada. Additionally, the H.C. Wainwright Annual Global Life Sciences Conference will be available on demand starting May 24, 2022, at 7:00 AM ET. Interested investors can access live webcasts of the presentations on the company’s website. Fate Therapeutics aims to develop innovative cell therapies for cancer treatment.

SAN DIEGO, May 06, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the following upcoming investor conferences:

• BofA Securities 2022 Healthcare Conference on Thursday, May 12, 2022 at 12:20 PM ET in Las Vegas, Nevada
• H.C. Wainwright Annual Global Life Sciences Conference available on demand on Tuesday, May 24, 2022 at 7:00 AM ET

A live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.

About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina@sternir.com

FAQ

What investor conferences will Fate Therapeutics present at in May 2022?

Fate Therapeutics will present at the BofA Securities 2022 Healthcare Conference on May 12, 2022, and the H.C. Wainwright Annual Global Life Sciences Conference on May 24, 2022.

What is the schedule for Fate Therapeutics at the BofA Securities Conference?

Fate Therapeutics will present at the BofA Securities Conference on May 12, 2022, at 12:20 PM ET.

When can I access the presentations from Fate Therapeutics' conferences?

Live webcasts of the presentations will be available on Fate Therapeutics' website shortly after the events.

What focus areas does Fate Therapeutics have in its immuno-oncology pipeline?

Fate Therapeutics focuses on developing off-the-shelf, iPSC-derived natural killer (NK) and T-cell product candidates targeting cancer therapies.

Where is Fate Therapeutics headquartered?

Fate Therapeutics is headquartered in San Diego, California.